AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02152735 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cleaning the uterine cavity
Description: These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
Study NCT02377635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anhydrous selenite
Description: 40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
Study NCT02377635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: 40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
Study NCT01739296 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neutral insole with subtalar strapping (sham)
Description: Neutral insole with subtalar strapping (sham)
Study NCT01739296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lateral wedge insole with subtalar strapping
Description: Lateral wedge insole with subtalar strapping
Study NCT00400361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Administered iv, either weekly or 3 weekly, at escalating doses (with a starting dose of 1mg/kg) (7 cohorts).
Study NCT02954926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
Study NCT03374241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM15211 or Placebo
Description: Long-acting tri-agonist
Study NCT01558336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: praziquantel
Description: praziquantel 40 mg/kg oral tablets
Study NCT01660334 — intervention group
Intervention type: DRUG
Intervention: Voriconazole
Description: Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily.
Study NCT04366856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1: Prone positioning
Description: the interventional group will be suggested to spend at least 6 hours a day in prone position
Study NCT04366856 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 2: No instruction regarding positioning
Description: group with no instruction regarding positioning (control group)
Study NCT00654537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT00654537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study NCT00654537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Study NCT02998450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMR-687
Description: 1 of 6 possible single doses administered orally following overnight fast
Study NCT02998450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.
Study NCT03066115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: See arm description.
Study NCT03676517 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: preoperative short-course radiotherapy
Description: 1-week short-course radiation (5 Gy x 5) plus 6-week XELOX (capecitabine 1,000mg/m2 and oxaliplatin 130mg/m2 every 3 weeks) chemotherapy before total mesorectal excision (TME)
Study NCT02470793 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Descemet Stripping Automated Endothelial Keratoplasty
Description: Descemet Stripping Automated Endothelial Keratoplasty
Study NCT02470793 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Descemet Membrane Endothelial Keratoplasty
Description: Descemet Membrane Endothelial Keratoplasty
Study NCT03150823 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upward Direct Current (Ascending Effect)
Description: Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the ascending stream direct current (Ascending effect) the proximal cathode and distal anode are placed, a excitatory effect on the nervous system being described in theory.
Study NCT03150823 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Downward Direct Current (Descending Effect)
Description: Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the descending stream direct current (Descending effect) the proximal anode and distal cathode are placed, a sedative and analgesic effect on the nervous system being described in theory.
Study NCT01839175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hexavalent vaccine
Description: 0.5 mL intramuscular injection at 2, 3 and 4 months of age (primary series) 0.5 mL intramuscular injection at 12 or 13 months of age (booster)
Study NCT01839175 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hexavalent vaccine
Description: 0.5 mL intramuscular injection at 2, 3 and 4 months of age (primary series) 0.5 mL intramuscular injection at 12 or 13 months of age (booster)
Study NCT03150823 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Direct Current
Description: Installation of electrotherapy equipment off (Sham tratment).
Study NCT05068375 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombophilia screening
Description: Genetic thrombophilia and acquired thrombophilia screening
Study NCT01370135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5mg intraocular Ranibizumab (Lucentis)
Description: short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rubeosis and neovascular glaucoma
Study NCT02002000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D (cholecalciferol)
Description: Patients from the vitamin D arm will receive an orally supplementation of 600 000 UI cholecalciferol in 3 doses: 200 000 UI at baseline (day 1), 200 000 UI on day 15 and 200 000 UI on day 30. Cholecalciferol will be presented in blisters, in a non-differentiable form in appearance and taste from placebo, either for the patient or the doctor
Study NCT02002000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, similar in appearance and taste to cholecalciferol
Description: Patients from the placebo arm will receive 3 doses of placebo to be taken orally: one at baseline (day 1), one on day 15, one on day 30. Placebo will be presented in blisters in a non-differentiable form in appearance and taste from cholecalciferol either for the patient or the doctor.
Study NCT02979236 — intervention group
Intervention type: DEVICE
Intervention: STENTYS Xposition S
Study NCT02593448 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NIRS during VOT
Description: Near infrared spectroscopy with INVOS oximeter during vascular occlusion test (VOT) on following timepoints:~1. 30 minutes after anaesthesia induction,~2. directly after the sternotomy,~3. during CPB - 20 minutes after aortic cross-clamping ,~4. 40 minutes after aortic cross-clamping,~5. 20 minutes after the release of the aortic cross-clamp,~6. 45 minutes after weaning of CPB.
Study NCT02593448 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIRS during VOT
Description: Near infrared spectroscopy with INVOS oximeter during vascular occlusion test (VOT) on following timepoints:~1. 30 minutes after anaesthesia induction,~2. directly after the sternotomy,~3. during CPB - 20 minutes after aortic cross-clamping ,~4. 40 minutes after aortic cross-clamping,~5. 20 minutes after the release of the aortic cross-clamp,~6. 45 minutes after weaning of CPB.
Study NCT00654537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Study NCT01459094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A (CANA/MET IR FDC tablet - fasting state) / B (CANA/MET IR FDC tablet - fed state)
Description: Treatment A: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally (by mouth) in a fasting state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 2.
Study NCT03066115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: See arm description.
Study NCT03066115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: See arm description.
Study NCT03066115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous Catheter
Description: Two intravenous catheters will be placed for each study visit. One catheter will be used for the intravenous infusion of study drugs (L-NMMA, Ketorolac, and Ascorbic Acid). The second catheter will be used to draw intermittent blood samples at 8-specific time points throughout each study visit to ensure pharmaceutical efficacy and examine systemic physiologic blood variables of interest.
Study NCT03066115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler Ultrasound
Description: MCAv will be measured via the transtemporal window while BAv will be measured through the transforaminal window with 2-MHz transcranial Doppler ultrasound probes (TCD, Neurovision model 500M, Multigon Industries, Inc.; Yonkers, NY, USA)
Study NCT03609008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levcromakalim
Description: Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
Study NCT03609008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
Study NCT03837431 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin slit
Description: Skin slit microscopy, RDT and PCR
Study NCT03837431 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dental broach
Description: Dental broach RDT and PCR
Study NCT03837431 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tape disc
Description: Tape disc PCR
Study NCT00738023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Diabetic subjects will be receive rosiglitazone for 6 weeks
Study NCT00738023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline 0.9%
Description: Normal saline 0.9% intravenous infusion at 40ml/hr for 48 hours
Study NCT00738023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: Intralipid 20% at 40ml/hr intravenously for 48 hours
Study NCT00536341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 2.5 mg orally (PO) daily, Days 8-28, Cycle 1; 5.0 mg PO daily, Days 8-28 Cycles 2-6
Study NCT00536341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 Cycle 1 (split over Day 1 \& Day 2); 500 mg/m2 Day 1 of Cycles 2-6
Study NCT00536341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 on Days 1, 2, and 3
Study NCT04115683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual Task Training
Description: 45 minutes of dual task training consisting of motor activities (walking, balance... etc.) with combination of cognitive activities (spelling words, image description, nomination, word generation, counting... etc.) at sime time.
Study NCT04115683 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single Task Training
Description: 45 minutes of single task training consisting of same motor activities (walking, balance... etc.)
Study NCT01839175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeisVac-C
Description: 0.5 mL intramuscular injection at 2 and 4 months of age
Study NCT01839175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13
Description: 0.5 mL intramuscular injection at 2 and 4 months of age (primary series) 0.5 mL intramuscular injection at 13 months of age (booster)
Study NCT01839175 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: 0.5 mL intramuscular injection at 2 and 4 months of age (primary series) 0.5 mL intramuscular injection at 13 months of age (booster)
Study NCT01839175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq
Description: 2 mL oral administration at 2, 3 and 4 months
Study NCT01839175 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq
Description: 2 mL oral administration at 2, 3 and 4 months
Study NCT01839175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix
Description: 0.5 mL intramuscular injection at 12 months
Study NCT01839175 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nimenrix
Description: 0.5 mL intramuscular injection at 12 months
Study NCT01839175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-RVAXPRO
Description: 0.5 mL intramuscular or subcutaneous injection at 13 months of age
Study NCT01839175 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-RVAXPRO
Description: 0.5 mL intramuscular or subcutaneous injection at 13 months of age
Study NCT02614287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC
Study NCT03435770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUSRA RFA needle
Description: A 19-gauge RFA electrode and a RF generator with a electrode that is needle-shaped and echogenic that allows EUS guided puncture of the target lesion. The active electrode tip is 1 cm in length. During ablation, the RF electrode is cooled and perfused internally with circulating chilled saline solution (0°C) delivered via a pump to maintain a constant temperature. A setting of 50W energy would be used for RFA and the duration of application is 10 seconds. Sequential applications of up to 7 times per session are allowed for complete ablation of the lesions.
Study NCT02020252 — intervention group
Intervention type: BEHAVIORAL
Intervention: Testing an interactive technology in a diverse health literary population
Description: Enrollment in therapeutic cancer trials remains low, and is especially challenging for patients with low health literacy. We tested an interactive technology designed for patients with diverse health literacy skills aimed at improving patient receptiveness, willingness, knowledge, self-efficacy and positive attitudes regarding clinical trials.
Study NCT04585412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron
Description: Pharmacokinetic study under fasting conditions
Study NCT04585412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Pharmacokinetic study under fasting conditions
Study NCT04292132 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: interforaminal placement of 2 implants
Study NCT04292132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant placement
Description: interforaminal placement of 2 implants
Study NCT04292132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate loading
Description: immediate loading with a locator retained mandibular overdenture
Study NCT04292132 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional loading
Description: conventional loading with a locator retained mandibular overdenture 3 months postoperatively
Study NCT01215344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE
Description: 1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle
Study NCT01215344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg by mouth on days 1-4 of each cycle
Study NCT01215344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg the day before and the day after receiving VELCADE
Study NCT01215344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DVT prophylaxis
Description: At least one asprin 81 mg per day. Other option per physician's choice
Study NCT01215344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Description: Zoledronic acid by IB or pamidronate by IV can be used as per standard of care.
Study NCT01215344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Description: 30 mg/m2 on day 4 of each cycle
Study NCT01215344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg by mouth on days 1-4, 8-11, and 15-18 of cycle 1 and days 1-4 on cycle 2-4
Study NCT01459094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state)
Description: Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fasting state on Day 1 of Treatment Period 2.
Study NCT03950635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Consume whole-foods, fiber-rich diet
Study NCT03950635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Consume high fat, low carbohydrate (ketogenic) diet
Study NCT03950635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00087217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study NCT00087217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00087217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00087217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04683705 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: 1. High-resolution ultrasound evaluation of the shoulder region to recognize the biceps tendon, subscapularis tendon, supraspinatus tendon, and infraspinatus tendon.~2. High-resolution ultrasound evaluation for the C5, C6 and C7 nerve roots and the suprascapular nerve over the supraclavicular fossa , in the supraspinatus fossa and in the infraspinatus fossa to obtain the nerve cross-sectional image.~3. Collecting the shoulder pain-related information, including physical examination results (bicipital groove tenderness, Speed test, Yergason's test, Empty can test, Neer test, Hawkins-Kennedy test and painful arc test) and status of disability using Shoulder Pain and Disability Index (SPADI).
Study NCT00628381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline supplementation
Description: L-citrulline, 1.8micromol/kg/min, during 8 hours continuously supplemented
Study NCT00628381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-alanine
Description: L-alanine enteral infusion, isocaloric dosage (3.6 micromol/kg/min), during 8 hours, continuously supplemented
Study NCT04582006 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Surgical treatment of morbid obesity.
Study NCT04162106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smoke management during laparoscopic cholecystectomy using the Ultravision™ System
Description: The Ultravision™ System will be used during the procedure to manage smoke generated as a result of the use of diathermy.